Montreal Cognitive Assessment (MoCA): Difference between revisions
No edit summary |
No edit summary |
||
| Line 20: | Line 20: | ||
* [[Huntington Disease|Huntington's disease]]<ref>Bezdicek O, Majerova V, Novak M, Nikolai T, Ruzicka E, Roth J. Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease. Appl Neuropsychol Adult. 2013 Jan 1;20(1):33-40.</ref> | * [[Huntington Disease|Huntington's disease]]<ref>Bezdicek O, Majerova V, Novak M, Nikolai T, Ruzicka E, Roth J. Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease. Appl Neuropsychol Adult. 2013 Jan 1;20(1):33-40.</ref> | ||
* [[Schizophrenia]]<ref>Yang Z, Abdul Rashid NA, Quek YF, Lam M, See YM, Maniam Y, Dauwels J, Tan BL, Lee J. Montreal Cognitive Assessment as a screening instrument for cognitive impairments in schizophrenia. Schizophr Res. 2018 Sep;199:58-63.</ref> | * [[Schizophrenia]]<ref>Yang Z, Abdul Rashid NA, Quek YF, Lam M, See YM, Maniam Y, Dauwels J, Tan BL, Lee J. Montreal Cognitive Assessment as a screening instrument for cognitive impairments in schizophrenia. Schizophr Res. 2018 Sep;199:58-63.</ref> | ||
* Brain tumors | * Brain tumors<ref>Olson RA, Chhanabhai T, McKenzie M. Feasibility study of the Montreal Cognitive Assessment (MoCA) in patients with brain metastases. Support Care Cancer. 2008 Nov;16(11):1273-8. </ref> | ||
* Systemic lupus erythematosus | * Systemic lupus erythematosus<ref>Paez-Venegas N, Jordan-Estrada B, Chavarria-Avila E, Perez-Vazquez F, Gómez-Bañuelos E, Medina-Dávalos R, Ontiveros-González JÁ, Diaz-Rubio GI, Navarro-Hernandez RE, Vázquez-Del Mercado M. The Montreal Cognitive Assessment Test: A Useful Tool in Screening of Cognitive Impairment in Patients With Systemic Lupus Erythematosus. J Clin Rheumatol. 2019 Dec;25(8):325-8.</ref> | ||
* Substance use disorders | * Substance use disorders | ||
* Idiopathic rapid eye movement sleep behavior disorder | * Idiopathic rapid eye movement sleep behavior disorder | ||
| Line 28: | Line 28: | ||
* Epilepsy | * Epilepsy | ||
* Chronic obstructive pulmonary disease | * Chronic obstructive pulmonary disease | ||
* | * HIV-associated neurocognitive disorders<ref>Rosca EC, Albarqouni L, Simu M. Montreal Cognitive Assessment (MoCA) for HIV-Associated Neurocognitive Disorders. Neuropsychol Rev. 2019 Sep;29(3):313-27.</ref> | ||
== Method of Use == | == Method of Use == | ||
Revision as of 07:00, 29 March 2022
Original Editor - Arnold Fredrick D'Souza
Top Contributors - Arnold Fredrick D'Souza, Lucinda hampton, Kim Jackson and Sultan Eylem Demirhan
This article or area is currently under construction and may only be partially complete. Please come back soon to see the finished work! (29/03/2022)
Objective[edit | edit source]
It was developed by Dr. Ziad S. Nasreddine and colleagues for quickly screening individuals for mild cognitive impairment.[1]
Intended Population[edit | edit source]
It can be used on the following populations:
- Older adults[2]
- Alzheimer's dementia[3]
- Vascular cognitive impairment[4]
- Stroke[5]
- Parkinson's disease[6]
- Progressive supranuclear palsy[7]
- Multiple system atrophy[7]
- Huntington's disease[8]
- Schizophrenia[9]
- Brain tumors[10]
- Systemic lupus erythematosus[11]
- Substance use disorders
- Idiopathic rapid eye movement sleep behavior disorder
- Obstructive sleep apnea
- Risk of falling
- Epilepsy
- Chronic obstructive pulmonary disease
- HIV-associated neurocognitive disorders[12]
Method of Use[edit | edit source]
It is a clinician-reported measure than takes about 10 minutes to administer
Reference[edit | edit source]
Evidence[edit | edit source]
Reliability[edit | edit source]
Validity[edit | edit source]
Responsiveness[edit | edit source]
Miscellaneous[edit | edit source]
The video below demonstrates the use of the MoCA. It has hardcoded closed captions.
Links[edit | edit source]
For more information on MoCA, click here to visit the official website.
References[edit | edit source]
- ↑ Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9.
- ↑ Feeney J, Savva GM, O'Regan C, King-Kallimanis B, Cronin H, Kenny RA. Measurement Error, Reliability, and Minimum Detectable Change in the Mini-Mental State Examination, Montreal Cognitive Assessment, and Color Trails Test among Community Living Middle-Aged and Older Adults. J Alzheimers Dis. 2016 May 31;53(3):1107-14.
- ↑ Lam B, Middleton LE, Masellis M, Stuss DT, Harry RD, Kiss A, Black SE. Criterion and convergent validity of the Montreal cognitive assessment with screening and standardized neuropsychological testing. J Am Geriatr Soc. 2013 Dec;61(12):2181-5.
- ↑ Koski L. Validity and applications of the Montreal cognitive assessment for the assessment of vascular cognitive impairment. Cerebrovasc Dis. 2013;36(1):6-18.
- ↑ Toglia J, Fitzgerald KA, O'Dell MW, Mastrogiovanni AR, Lin CD. The Mini-Mental State Examination and Montreal Cognitive Assessment in persons with mild subacute stroke: relationship to functional outcome. Arch Phys Med Rehabil. 2011 May;92(5):792-8.
- ↑ Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord. 2008 May 15;23(7):1043-6.
- ↑ 7.0 7.1 Fiorenzato E, Weis L, Falup-Pecurariu C, Diaconu S, Siri C, Reali E, Pezzoli G, Bisiacchi P, Antonini A, Biundo R. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy. J Neural Transm (Vienna). 2016 Dec;123(12):1435-42.
- ↑ Bezdicek O, Majerova V, Novak M, Nikolai T, Ruzicka E, Roth J. Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease. Appl Neuropsychol Adult. 2013 Jan 1;20(1):33-40.
- ↑ Yang Z, Abdul Rashid NA, Quek YF, Lam M, See YM, Maniam Y, Dauwels J, Tan BL, Lee J. Montreal Cognitive Assessment as a screening instrument for cognitive impairments in schizophrenia. Schizophr Res. 2018 Sep;199:58-63.
- ↑ Olson RA, Chhanabhai T, McKenzie M. Feasibility study of the Montreal Cognitive Assessment (MoCA) in patients with brain metastases. Support Care Cancer. 2008 Nov;16(11):1273-8.
- ↑ Paez-Venegas N, Jordan-Estrada B, Chavarria-Avila E, Perez-Vazquez F, Gómez-Bañuelos E, Medina-Dávalos R, Ontiveros-González JÁ, Diaz-Rubio GI, Navarro-Hernandez RE, Vázquez-Del Mercado M. The Montreal Cognitive Assessment Test: A Useful Tool in Screening of Cognitive Impairment in Patients With Systemic Lupus Erythematosus. J Clin Rheumatol. 2019 Dec;25(8):325-8.
- ↑ Rosca EC, Albarqouni L, Simu M. Montreal Cognitive Assessment (MoCA) for HIV-Associated Neurocognitive Disorders. Neuropsychol Rev. 2019 Sep;29(3):313-27.
